Home / Articles / Targeted nuclear medicine. Seek and destroy

Targeted nuclear medicine. Seek and destroy

Vladimir Maksimilianovich Tolmachev 1, 2, 
Vladimir Maksimilianovich Tolmachev
Vladimir Ivanovich Chernov 2, 3, 
Vladimir Ivanovich Chernov
Sergei Mikhailovich Deyev 2, 4
Sergei Mikhailovich Deyev
1 Department of Immunology, Genetics and Pathology, Uppsala University, Sweden
2 Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russian Federation
3 Tomsk National Research Medical Center of the Russian Academy of Sciences, Cancer Research Institute
4 M. M. Shemyakin and Yu. A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow
Published 30 November 2021
42
Cite this
GOST
 | 
Cite this
GOST
Tolmachev V. M., Chernov V. I., Deyev S. M. Targeted nuclear medicine. Seek and destroy // Russian Chemical Reviews. 2021. Vol. 91. No. 3. RCR5034
GOST all authors (up to 50)
Tolmachev V. M., Chernov V. I., Deyev S. M. Targeted nuclear medicine. Seek and destroy // Russian Chemical Reviews. 2021. Vol. 91. No. 3. RCR5034
RIS
 | 
Cite this
RIS
TY - JOUR
DO - 10.1070/RCR5034
UR - https://rcr.colab.ws/publications/10.1070/RCR5034
TI - Targeted nuclear medicine. Seek and destroy
T2 - Russian Chemical Reviews
AU - Tolmachev, Vladimir Maksimilianovich
AU - Chernov, Vladimir Ivanovich
AU - Deyev, Sergei Mikhailovich
PY - 2021
DA - 2021/11/30
PB - ANO Editorial Board of the journal Uspekhi Khimii
SP - RCR5034
IS - 3
VL - 91
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors)
@article{2021_Tolmachev,
author = {Vladimir Maksimilianovich Tolmachev and Vladimir Ivanovich Chernov and Sergei Mikhailovich Deyev},
title = {Targeted nuclear medicine. Seek and destroy},
journal = {Russian Chemical Reviews},
year = {2021},
volume = {91},
publisher = {ANO Editorial Board of the journal Uspekhi Khimii},
month = {Nov},
url = {https://rcr.colab.ws/publications/10.1070/RCR5034},
number = {3},
doi = {10.1070/RCR5034}
}
MLA
Cite this
MLA
Tolmachev, Vladimir Maksimilianovich, et al. “Targeted nuclear medicine. Seek and destroy.” Russian Chemical Reviews, vol. 91, no. 3, Nov. 2021, p. RCR5034. https://rcr.colab.ws/publications/10.1070/RCR5034.
Views / Downloads
45 / 28

Abstract

The targeted delivery of radionuclides to tumours holds great promise for diagnosis and treatment of malignant neoplasms. The development of scaffold proteins has significantly simplified the design of targeting agents with desirable properties. This review comprehensively describes the key aspects of the design of radionuclide compounds, including classification of radionuclides, methodology for their attachment to targeting agents and characteristics of these agents that affect their behaviour in the body. Various targeting molecules are compared in terms of their ability to specifically find malignant foci in the body. The most recent achievements of cancer theranostics that aim at increasing the selectivity of antitumour effect are described, such as the fusion of targeting scaffold proteins with the albumin-binding domain and pretargeting. Special attention is paid to the creation of targeted radionanomaterials. Advantages and disadvantages of different strategies are analyzed and approaches for improving the delivery to tumours and for minimizing the undesirable impact on healthy organs and tissues are proposed. Particular emphasis is placed on the results of studies published in 2020--2021 that have not yet been covered by reviews.

The bibliography includes 191 references.

Keywords

ADAPT
affibody
albumin-binding domains
DARPin
pretargeting
radionuclide
scaffold protein
targeting

Funders

Russian Foundation for Basic Research
20-14-50055

References

1.
The development of immunoconjugates for targeted cancer therapy
Smaglo B.G., Aldeghaither D., Weiner L.M.
Nature Reviews Clinical Oncology , 2014
2.
Immunogenicity of therapeutic recombinant immunotoxins
Mazor R., Onda M., Pastan I.
Immunological Reviews , 2016
3.
Design of Targeted B Cell Killing Agents
Stepanov A.V., Belogurov A.A., Ponomarenko N.A., Stremovskiy O.A., Kozlov L.V., Bichucher A.M., Dmitriev S.E., Smirnov I.V., Shamborant O.G., Balabashin D.S., Sashchenko L.P., Tonevitsky A.G., Friboulet A., Gabibov A.G., Deyev S.M., et. al.
PLoS ONE , 2011
4.
Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape
Shramova E., Proshkina G., Shipunova V., Ryabova A., Kamyshinsky R., Konevega A., Schulga A., Konovalova E., Telegin G., Deyev S.
Cancers , 2020
5.
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D., Diéras V., Guardino E., Fang L., Lu M.W., Olsen S., Blackwell K.
New England Journal of Medicine , 2012
7.
Radioimmunotherapy of human tumours
Larson S.M., Carrasquillo J.A., Cheung N.V., Press O.W.
Nature Reviews Cancer , 2015
8.
rcr_91_3_RCR5034bib8
Lishmanov
2010
9.
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Giordano S.H., Temin S., Kirshner J.J., Chandarlapaty S., Crews J.R., Davidson N.E., Esteva F.J., Gonzalez-Angulo A.M., Krop I., Levinson J., Lin N.U., Modi S., Patt D.A., Perez E.A., Perlmutter J., et. al.
Journal of Clinical Oncology , 2014
10.
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Van Cutsem E., Bang Y., Feng-yi F., Xu J.M., Lee K., Jiao S., Chong J.L., López-Sanchez R.I., Price T., Gladkov O., Stoss O., Hill J., Ng V., Lehle M., Thomas M., et. al.
Gastric Cancer , 2014
11.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang Y., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Rüschoff J., et. al.
The Lancet , 2010
12.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Gianni L., Pienkowski T., Im Y., Roman L., Tseng L., Liu M., Lluch A., Staroslawska E., de la Haba-Rodriguez J., Im S., Pedrini J.L., Poirier B., Morandi P., Semiglazov V., Srimuninnimit V., et. al.
The Lancet Oncology , 2012
13.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
de Azambuja E., Holmes A.P., Piccart-Gebhart M., Holmes E., Di Cosimo S., Swaby R.F., Untch M., Jackisch C., Lang I., Smith I., Boyle F., Xu B., Barrios C.H., Perez E.A., Azim H.A., et. al.
The Lancet Oncology , 2014
14.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L.
Science , 1987
15.
When to order a biopsy to characterise a metastatic relapse in breast cancer
Foukakis T., Åström G., Lindström L., Hatschek T., Bergh J.
Annals of Oncology , 2012
16.
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis
Houssami N., Macaskill P., Balleine R.L., Bilous M., Pegram M.D.
Breast Cancer Research and Treatment , 2011
17.
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
Wilking U., Karlsson E., Skoog L., Hatschek T., Lidbrink E., Elmberger G., Johansson H., Lindström L., Bergh J.
Breast Cancer Research and Treatment , 2010
20.
Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond
Garousi J., Orlova A., Frejd F.Y., Tolmachev V.
EJNMMI Radiopharmacy and Chemistry , 2020
21.
Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
Krasniqi A., D’Huyvetter M., Devoogdt N., Frejd F.Y., Sörensen J., Orlova A., Keyaerts M., Tolmachev V.
Journal of Nuclear Medicine , 2018
22.
Synthesis of11C,18F,15O, and13N Radiolabels for Positron Emission Tomography
Miller P., Long N., Vilar R., Gee A.
Angewandte Chemie - International Edition , 2008
23.
Immuno-PET: a navigator in monoclonal antibody development and applications.
van Dongen G.A., Visser G.W., Lub-de Hooge M.N., de Vries E.G., Perk L.R.
Oncologist , 2007
24.
Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods
Tolmachev V., Stone-Elander S.
Biochimica et Biophysica Acta - General Subjects , 2010
25.
Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
Lamberts L.E., Williams S.P., Terwisscha van Scheltinga A.G., Lub-de Hooge M.N., Schröder C.P., Gietema J.A., Brouwers A.H., de Vries E.G.
Journal of Clinical Oncology , 2015
26.
The Role of 89Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals
van Dongen G.A., Beaino W., Windhorst A.D., Zwezerijnen G.J., Oprea-Lager D.E., Hendrikse N.H., van Kuijk C., Boellaard R., Huisman M.C., Vugts D.J.
Journal of Nuclear Medicine , 2020
28.
ImmunoPET: Concept, Design, and Applications
Wei W., Rosenkrans Z.T., Liu J., Huang G., Luo Q., Cai W.
Chemical Reviews , 2020
29.
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., van Dongen G.A., Schröder C.P., Lub-de Hooge M.N., de Vries E.G.
Clinical Pharmacology and Therapeutics , 2010
30.
Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma
Jansen M.H., Veldhuijzen van Zanten S.E., van Vuurden D.G., Huisman M.C., Vugts D.J., Hoekstra O.S., van Dongen G.A., Kaspers G.L.
Journal of Nuclear Medicine , 2016
31.
rcr_91_3_RCR5034bib31
Verel
J. Nucl. Med. , 2003
33.
rcr_91_3_RCR5034bib33
Tolmachev
2008
35.
The Radiobiology of Targeted Radiotherapy
Wheldon T.E., O'Donoghue J.A.
International Journal of Radiation Biology , 1990
36.
The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y.
Wheldon T.E., O'Donoghue J.A., Barrette A., Michalowski A.S.
Radiotherapy and Oncology , 1991
37.
rcr_91_3_RCR5034bib37
O’Donoghue
J. Nucl. Med. , 1995
38.
Radionuclides and carrier molecules for therapy
Zweit J.
Physics in Medicine and Biology , 1996
39.
Recent advances in radionuclide therapy
Srivastava S., Dadachova E.
Seminars in Nuclear Medicine , 2001
40.
rcr_91_3_RCR5034bib40
41.
Clinical radioimmunotherapy—the role of radiobiology
Pouget J., Navarro-Teulon I., Bardiès M., Chouin N., Cartron G., Pèlegrin A., Azria D.
Nature Reviews Clinical Oncology , 2011
42.
A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?
45.
Label stability in serum of four radionuclides on DTPA-coupled antibodies—An evaluation
Hnatowich D.J.
International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology , 1986
46.
Can a cysteine challenge assay predict the in vivo behavior of 99mTc-labeled antibodies?
Hnatowich D.J., Virzi F., Fogarasi M., Rusckowski M., Winnard P.
Nuclear Medicine and Biology , 1994
47.
Cationic radionuclides and ligands for targeted therapeutic radiopharmaceuticals
Egorova B.V., Fedorova O.A., Kalmykov S.N.
Russian Chemical Reviews , 2019
51.
Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu‐DOTAGA‐PEG 2 ‐RM26
Mitran B., Rinne S.S., Konijnenberg M.W., Maina T., Nock B.A., Altai M., Vorobyeva A., Larhed M., Tolmachev V., Jong M., Rosenström U., Orlova A.
International Journal of Cancer , 2019
52.
Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting
Grob N.M., Häussinger D., Deupi X., Schibli R., Behe M., Mindt T.L.
Journal of Medicinal Chemistry , 2020
53.
rcr_91_3_RCR5034bib53
Smith-Jones
Cancer Res. , 2000
54.
DOTAGA-Trastuzumab. A New Antibody Conjugate Targeting HER2/Neu Antigen for Diagnostic Purposes
Moreau M., Raguin O., Vrigneaud J., Collin B., Bernhard C., Tizon X., Boschetti F., Duchamp O., Brunotte F., Denat F.
Bioconjugate Chemistry , 2012
55.
Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma
Lindenblatt D., Terraneo N., Pellegrini G., Cohrs S., Spycher P.R., Vukovic D., Béhé M., Schibli R., Grünberg J.
BMC Cancer , 2018
56.
[111In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors
Maina T., Cescato R., Waser B., Tatsi A., Kaloudi A., Krenning E.P., de Jong M., Nock B.A., Reubi J.C.
Journal of Medicinal Chemistry , 2014
57.
Metal-Ion-Dependent Biological Properties of a Chelator-Derived Somatostatin Analogue for Tumour Targeting
Heppeler A., André J., Buschmann I., Wang X., Reubi J., Hennig M., Kaden T., Maecke H.
Chemistry - A European Journal , 2008
58.
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
Umbricht C.A., Benešová M., Schmid R.M., Türler A., Schibli R., van der Meulen N.P., Müller C.
EJNMMI Research , 2017
59.
A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts
Loktev A., Lindner T., Mier W., Debus J., Altmann A., Jäger D., Giesel F., Kratochwil C., Barthe P., Roumestand C., Haberkorn U.
Journal of Nuclear Medicine , 2018
60.
Therapeutic Potential of 47Sc in Comparison to 177Lu and 90Y: Preclinical Investigations
Siwowska K., Guzik P., Domnanich K.A., Monné Rodríguez J.M., Bernhardt P., Ponsard B., Hasler R., Borgna F., Schibli R., Köster U., van der Meulen N.P., Müller C.
Pharmaceutics , 2019
61.
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
Benešová M., Schäfer M., Bauder-Wüst U., Afshar-Oromieh A., Kratochwil C., Mier W., Haberkorn U., Kopka K., Eder M.
Journal of Nuclear Medicine , 2015
62.
Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
Chan H.S., Konijnenberg M.W., de Blois E., Koelewijn S., Baum R.P., Morgenstern A., Bruchertseifer F., Breeman W.A., de Jong M.
EJNMMI Research , 2016
63.
Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer
Stenberg V.Y., Juzeniene A., Chen Q., Yang X., Bruland Ø.S., Larsen R.H.
Journal of Labelled Compounds and Radiopharmaceuticals , 2020
64.
Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
Qin Y., Imobersteg S., Blanc A., Frank S., Schibli R., Béhé M.P., Grzmil M.
Pharmaceutics , 2020
66.
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
Hens M., Vaidyanathan G., Zhao X., Bigner D.D., Zalutsky M.R.
Nuclear Medicine and Biology , 2010
67.
Preclinical Studies Targeting Normal and Leukemic Hematopoietic Cells with Yttrium-90-Labeled anti-CD45 Antibody in Vitro and in Vivo in Nude Mice
Vallera D., Elson M., Brechbiel M., Dusenbery K., Burns L., Skubitz K., Jaszcz W., Ramsay N., Panoskaltsis-Mortari A., Kuroki D., Wagner J., Kersey J.
Cancer Biotherapy and Radiopharmaceuticals , 2003
68.
Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)
Lansigan F., Costa C.A., Zaki B.I., Yen S.P., Winer E.S., Ryan H., Findley D., Metzler S.R., Shaw L., Toaso B., MacKenzie T.A., Chen Y., Beaven A.W.
Clinical Cancer Research , 2019
70.
The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy
Tolmachev V., Wållberg H., Andersson K., Wennborg A., Lundqvist H., Orlova A.
European Journal of Nuclear Medicine and Molecular Imaging , 2009
71.
[177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells
Persson M., Tolmachev V., Andersson K., Gedda L., Sandström M., Carlsson J.
European Journal of Nuclear Medicine and Molecular Imaging , 2005
72.
Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A″-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478
Lee F.T., Mountain A.J., Kelly M.P., Hall C., Rigopoulos A., Johns T.G., Smyth F.E., Brechbiel M.W., Nice E.C., Burgess A.W., Scott A.M.
Clinical Cancer Research , 2005
73.
PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab
Nayak T.K., Regino C.A., Wong K.J., Milenic D.E., Garmestani K., Baidoo K.E., Szajek L.P., Brechbiel M.W.
European Journal of Nuclear Medicine and Molecular Imaging , 2010
74.
89Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89Zr Radiochemistry
Heskamp S., Raavé R., Boerman O., Rijpkema M., Goncalves V., Denat F.
Bioconjugate Chemistry , 2017
75.
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Dijkers E.C., Kosterink J.G., Rademaker A.P., Perk L.R., van Dongen G.A., Bart J., de Jong J.R., de Vries E.G., Lub-de Hooge M.N.
Journal of Nuclear Medicine , 2009
76.
Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET
Vugts D.J., Klaver C., Sewing C., Poot A.J., Adamzek K., Huegli S., Mari C., Visser G.W., Valverde I.E., Gasser G., Mindt T.L., van Dongen G.A.
European Journal of Nuclear Medicine and Molecular Imaging , 2016
77.
Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET
Raavé R., Sandker G., Adumeau P., Jacobsen C.B., Mangin F., Meyer M., Moreau M., Bernhard C., Da Costa L., Dubois A., Goncalves V., Gustafsson M., Rijpkema M., Boerman O., Chambron J., et. al.
European Journal of Nuclear Medicine and Molecular Imaging , 2019
78.
rcr_91_3_RCR5034bib78
Malmberg
Int. J. Oncol. , 2011
79.
Radioimmunoconjugates for treating cancer: recent advances and current opportunities
Bourgeois M., Bailly C., Frindel M., Guerard F., Chérel M., Faivre-Chauvet A., Kraeber-Bodéré F., Bodet-Milin C.
Expert Opinion on Biological Therapy , 2017
80.
rcr_91_3_RCR5034bib80
Wester
J. Nucl. Med. , 2005
81.
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
Kunikowska J., Królicki L., Hubalewska-Dydejczyk A., Mikołajczak R., Sowa-Staszczak A., Pawlak D.
European Journal of Nuclear Medicine and Molecular Imaging , 2011
82.
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Kratochwil C., Bruchertseifer F., Rathke H., Bronzel M., Apostolidis C., Weichert W., Haberkorn U., Giesel F.L., Morgenstern A.
Journal of Nuclear Medicine , 2017
83.
Radiation Dosimetry for177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
Okamoto S., Thieme A., Allmann J., D’Alessandria C., Maurer T., Retz M., Tauber R., Heck M.M., Wester H., Tamaki N., Fendler W.P., Herrmann K., Pfob C.H., Scheidhauer K., Schwaiger M., et. al.
Journal of Nuclear Medicine , 2016
84.
Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer
Rahbar K., Weckesser M., Huss S., Semjonow A., Breyholz H., Schrader A.J., Schäfers M., Bögemann M.
Journal of Nuclear Medicine , 2016
86.
Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain
Nord K., Gunneriusson E., Ringdahl J., Ståhl S., Uhlén M., Nygren P.
Nature Biotechnology , 1997
87.
Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule
Orlova A., Magnusson M., Eriksson T.L., Nilsson M., Larsson B., Höidén-Guthenberg I., Widström C., Carlsson J., Tolmachev V., Ståhl S., Nilsson F.Y.
Cancer Research , 2006
88.
Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties
Wållberg H., Orlova A., Altai M., Hosseinimehr S.J., Widström C., Malmberg J., Ståhl S., Tolmachev V.
Journal of Nuclear Medicine , 2011
89.
Directed Evolution to Low Nanomolar Affinity of a Tumor-Targeting Epidermal Growth Factor Receptor-Binding Affibody Molecule
Friedman M., Orlova A., Johansson E., Eriksson T.L., Höidén-Guthenberg I., Tolmachev V., Nilsson F.Y., Ståhl S.
Journal of Molecular Biology , 2008
90.
Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry
Tolmachev V., Friedman M., Sandström M., Eriksson T.L., Rosik D., Hodik M., Ståhl S., Frejd F.Y., Orlova A.
Journal of Nuclear Medicine , 2009
91.
Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount
Tolmachev V., Rosik D., Wållberg H., Sjöberg A., Sandström M., Hansson M., Wennborg A., Orlova A.
European Journal of Nuclear Medicine and Molecular Imaging , 2009
92.
Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification
Malm M., Kronqvist N., Lindberg H., Gudmundsdotter L., Bass T., Frejd F.Y., Höidén-Guthenberg I., Varasteh Z., Orlova A., Tolmachev V., Ståhl S., Löfblom J.
PLoS ONE , 2013
93.
Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551
Tolmachev V., Malmberg J., Hofström C., Abrahmsén L., Bergman T., Sjöberg A., Sandström M., Gräslund T., Orlova A.
Journal of Nuclear Medicine , 2011
94.
Imaging of Platelet-Derived Growth Factor Receptor β Expression in Glioblastoma Xenografts Using Affibody Molecule 111In-DOTA-Z09591
Tolmachev V., Varasteh Z., Honarvar H., Hosseinimehr S.J., Eriksson O., Jonasson P., Frejd F.Y., Abrahmsen L., Orlova A.
Journal of Nuclear Medicine , 2014
95.
Mitran B., Güler R., Roche F.P., Lindström E., Selvaraju R.K., Fleetwood F., Rinne S.S., Claesson-Welsh L., Tolmachev V., Ståhl S., Orlova A., Löfblom J.
Theranostics , 2018
96.
In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
González Trotter D.E., Meng X., McQuade P., Rubins D., Klimas M., Zeng Z., Connolly B.M., Miller P.J., O’Malley S.S., Lin S., Getty K.L., Fayadat-Dilman L., Liang L., Wahlberg E., Widmark O., et. al.
Journal of Nuclear Medicine , 2017
97.
Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX
Garousi J., Honarvar H., Andersson K.G., Mitran B., Orlova A., Buijs J., Löfblom J., Frejd F.Y., Tolmachev V.
Molecular Pharmaceutics , 2016
98.
Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts
Garousi J., Huizing F.J., Vorobyeva A., Mitran B., Andersson K.G., Leitao C.D., Frejd F.Y., Löfblom J., Bussink J., Orlova A., Heskamp S., Tolmachev V.
Scientific Reports , 2019
101.
In vivo imaging with antibodies and engineered fragments
102.
PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology
Rinne S.S., Orlova A., Tolmachev V.
International Journal of Molecular Sciences , 2021
103.
The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer
104.
Engineering of Bispecific Affinity Proteins with High Affinity for ERBB2 and Adaptable Binding to Albumin
Nilvebrant J., Åstrand M., Georgieva-Kotseva M., Björnmalm M., Löfblom J., Hober S.
PLoS ONE , 2014
105.
ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers
Garousi J., Lindbo S., Nilvebrant J., Åstrand M., Buijs J., Sandström M., Honarvar H., Orlova A., Tolmachev V., Hober S.
Cancer Research , 2015
106.
Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins
Lindbo S., Garousi J., Åstrand M., Honarvar H., Orlova A., Hober S., Tolmachev V.
Bioconjugate Chemistry , 2016
107.
Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with 111In and 68Ga
Lindbo S., Garousi J., Mitran B., Vorobyeva A., Oroujeni M., Orlova A., Hober S., Tolmachev V.
Molecular Pharmaceutics , 2018
108.
Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours
Garousi J., Lindbo S., Borin J., von Witting E., Vorobyeva A., Oroujeni M., Mitran B., Orlova A., Buijs J., Tolmachev V., Hober S.
European Journal of Pharmaceutics and Biopharmaceutics , 2019
109.
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules
Tolmachev V., Mume E., Sjöberg S., Frejd F.Y., Orlova A.
European Journal of Nuclear Medicine and Molecular Imaging , 2008
110.
Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size
Zahnd C., Kawe M., Stumpp M.T., de Pasquale C., Tamaskovic R., Nagy-Davidescu G., Dreier B., Schibli R., Binz H.K., Waibel R., Plückthun A.
Cancer Research , 2010
111.
Efficient Selection of DARPins with Sub-nanomolar Affinities using SRP Phage Display
Steiner D., Forrer P., Plückthun A.
Journal of Molecular Biology , 2008
112.
DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency.
Stefan N., Martin-Killias P., Wyss-Stoeckle S., Honegger A., Zangemeister-Wittke U., Plückthun A.
Journal of Molecular Biology , 2011
113.
Crystal structures of HER3 extracellular domain 4 in complex with the designed ankyrin-repeat protein D5
Radom F., Vonrhein C., Mittl P.R., Plückthun A.
Acta Crystallographica Section F:Structural Biology Communications , 2021
114.
Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging
Goldstein R., Sosabowski J., Livanos M., Leyton J., Vigor K., Bhavsar G., Nagy-Davidescu G., Rashid M., Miranda E., Yeung J., Tolner B., Plückthun A., Mather S., Meyer T., Chester K., et. al.
European Journal of Nuclear Medicine and Molecular Imaging , 2014
115.
rcr_91_3_RCR5034bib115
Vorobyeva
Contrast Media Mol. Imaging , 2018
116.
Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
Deyev S., Vorobyeva A., Schulga A., Proshkina G., Güler R., Löfblom J., Mitran B., Garousi J., Altai M., Buijs J., Chernov V., Orlova A., Tolmachev V.
Molecular Pharmaceutics , 2019
117.
Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
Deyev S.M., Vorobyeva A., Schulga A., Abouzayed A., Günther T., Garousi J., Konovalova E., Ding H., Gräslund T., Orlova A., Tolmachev V.
International Journal of Biological Macromolecules , 2020
118.
Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1
Vorobyeva A., Konovalova E., Xu T., Schulga A., Altai M., Garousi J., Rinne S.S., Orlova A., Tolmachev V., Deyev S.
International Journal of Molecular Sciences , 2020
119.
Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1
Vorobyeva A., Bezverkhniaia E., Konovalova E., Schulga A., Garousi J., Vorontsova O., Abouzayed A., Orlova A., Deyev S., Tolmachev V.
Molecules , 2020
120.
99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule
Engfeldt T., Tran T., Orlova A., Widström C., Feldwisch J., Abrahmsen L., Wennborg A., Karlström A.E., Tolmachev V.
European Journal of Nuclear Medicine and Molecular Imaging , 2007
121.
188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment
Altai M., Wållberg H., Honarvar H., Strand J., Orlova A., Varasteh Z., Sandström M., Löfblom J., Larsson E., Strand S., Lubberink M., Ståhl S., Tolmachev V.
Journal of Nuclear Medicine , 2014
122.
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Sörensen J., Sandberg D., Sandström M., Wennborg A., Feldwisch J., Tolmachev V., Åström G., Lubberink M., Garske-Román U., Carlsson J., Lindman H.
Journal of Nuclear Medicine , 2014
123.
Sörensen J., Velikyan I., Sandberg D., Wennborg A., Feldwisch J., Tolmachev V., Orlova A., Sandström M., Lubberink M., Olofsson H., Carlsson J., Lindman H.
Theranostics , 2015
124.
Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients
Sandström M., Lindskog K., Velikyan I., Wennborg A., Feldwisch J., Sandberg D., Tolmachev V., Orlova A., Sörensen J., Carlsson J., Lindman H., Lubberink M.
Journal of Nuclear Medicine , 2016
125.
rcr_91_3_RCR5034bib125
Bragina
2021
126.
Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer
Bragina O., von Witting E., Garousi J., Zelchan R., Sandström M., Orlova A., Medvedeva A., Doroshenko A., Vorobyeva A., Lindbo S., Borin J., Tarabanovskaya N., Sörensen J., Hober S., Chernov V., et. al.
Journal of Nuclear Medicine , 2020
127.
Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein
Vorobyeva A., Oroujeni M., Lindbo S., Hober S., Xu T., Liu Y., Rinne S.S., Garousi J.
Molecules , 2020
128.
On the prevention of kidney uptake of radiolabeled DARPins
Altai M., Garousi J., Rinne S.S., Schulga A., Deyev S., Vorobyeva A.
EJNMMI Research , 2020
130.
Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule
Tolmachev V., Orlova A., Pehrson R., Galli J., Baastrup B., Andersson K., Sandström M., Rosik D., Carlsson J., Lundqvist H., Wennborg A., Nilsson F.Y.
Cancer Research , 2007
131.
Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein
Orlova A., Jonsson A., Rosik D., Lundqvist H., Lindborg M., Abrahmsen L., Ekblad C., Frejd F.Y., Tolmachev V.
Journal of Nuclear Medicine , 2013
132.
Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody® Molecules 177Lu-ABY-271 and 177Lu-ABY-027: Impact of DOTA Position on ABD Domain
Liu Y., Vorobyeva A., Xu T., Orlova A., Loftenius A., Bengtsson T., Jonasson P., Tolmachev V., Frejd F.Y.
Pharmaceutics , 2021
133.
Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle
Garousi J., von Witting E., Borin J., Vorobyeva A., Altai M., Vorontsova O., Konijnenberg M.W., Oroujeni M., Orlova A., Tolmachev V., Hober S.
Biomaterials , 2021
134.
Pretargeted Imaging and Therapy
Altai M., Membreno R., Cook B., Tolmachev V., Zeglis B.M.
Journal of Nuclear Medicine , 2017
135.
Feasibility of Affibody-Based Bioorthogonal Chemistry–Mediated Radionuclide Pretargeting
Altai M., Perols A., Tsourma M., Mitran B., Honarvar H., Robillard M., Rossin R., ten Hoeve W., Lubberink M., Orlova A., Karlström A.E., Tolmachev V.
Journal of Nuclear Medicine , 2015
136.
Honarvar H., Westerlund K., Altai M., Sandström M., Orlova A., Tolmachev V., Karlström A.E.
Theranostics , 2015
137.
Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid–Mediated Pretargeting: In Vivo Proof of Principle
Westerlund K., Altai M., Mitran B., Konijnenberg M., Oroujeni M., Atterby C., de Jong M., Orlova A., Mattsson J., Micke P., Karlström A.E., Tolmachev V.
Journal of Nuclear Medicine , 2018
138.
Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting
Tano H., Oroujeni M., Vorobyeva A., Westerlund K., Liu Y., Xu T., Vasconcelos D., Orlova A., Karlström A.E., Tolmachev V.
Cancers , 2021
139.
Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-Labeled hLL2 (Epratuzumab) in Nude Mice with CD22-Positive Lymphoma
Postema E.J., Frielink C., Oyen W.J., Raemaekers J.M., Goldenberg D.M., Corstens F.H., Boerman O.C.
Cancer Biotherapy and Radiopharmaceuticals , 2003
140.
rcr_91_3_RCR5034bib140
Koppe
J. Nucl. Med. , 2004
141.
rcr_91_3_RCR5034bib141
Meijs
J. Nucl. Med. , 1997
143.
Bensch F., Smeenk M.M., van Es S.C., de Jong J.R., Schröder C.P., Oosting S.F., Lub-de Hooge M.N., Menke-van der Houven van Oordt C.W., Brouwers A.H., Boellaard R., de Vries E.G.
Theranostics , 2018
146.
Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label
Lindbo S., Garousi J., Mitran B., Altai M., Buijs J., Orlova A., Hober S., Tolmachev V.
Journal of Nuclear Medicine , 2017
148.
Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging
Vorobyeva, Schulga, Rinne, Günther, Orlova, Deyev, Tolmachev
International Journal of Molecular Sciences , 2019
149.
rcr_91_3_RCR5034bib149
Vorobyeva
Int. J. Oncol. , 2019
150.
Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
Strand J., Nordeman P., Honarvar H., Altai M., Orlova A., Larhed M., Tolmachev V.
ChemistryOpen , 2015
151.
Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)–carbonyl complex
Waibel R., Alberto R., Willuda J., Finnern R., Schibli R., Stichelberger A., Egli A., Abram U., Mach J., Plückthun A., Schubiger P.A.
Nature Biotechnology , 1999
152.
Design of multivalent complexes using the barnase·barstar module
Deyev S.M., Waibel R., Lebedenko E.N., Schubiger A.P., Plückthun A.
Nature Biotechnology , 2003
153.
Optimising the radiolabelling properties of technetium tricarbonyl and His-tagged proteins
Badar A., Williams J., de Rosales R.T., Tavaré R., Kampmeier F., Blower P.J., Mullen G.E.
EJNMMI Research , 2014
154.
rcr_91_3_RCR5034bib154
Orlova
J. Nucl. Med. , 2006
155.
99mTc-maEEE-ZHER2:342, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors
Tran T., Engfeldt T., Orlova A., Sandström M., Feldwisch J., Abrahmsén L., Wennborg A., Tolmachev V., Karlström A.E.
Bioconjugate Chemistry , 2007
156.
HEHEHE-Tagged Affibody Molecule May Be Purified by IMAC, Is Conveniently Labeled with [99mTc(CO)3]+, and Shows Improved Biodistribution with Reduced Hepatic Radioactivity Accumulation
Tolmachev V., Hofström C., Malmberg J., Ahlgren S., Hosseinimehr S.J., Sandström M., Abrahmsén L., Orlova A., Gräslund T.
Bioconjugate Chemistry , 2010
157.
HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [99mTc(CO)3]+-Labeled Affibody Molecules
Hofström C., Altai M., Honarvar H., Strand J., Malmberg J., Hosseinimehr S.J., Orlova A., Gräslund T., Tolmachev V.
Journal of Medicinal Chemistry , 2013
158.
Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3
Vorobyeva A., Schulga A., Konovalova E., Güler R., Löfblom J., Sandström M., Garousi J., Chernov V., Bragina O., Orlova A., Tolmachev V., Deyev S.M.
Scientific Reports , 2019
159.
Synthesis, Characterization, and Selective Delivery of DARPin–Gold Nanoparticle Conjugates to Cancer Cells
Deyev S., Proshkina G., Ryabova A., Tavanti F., Menziani M.C., Eidelshtein G., Avishai G., Kotlyar A.
Bioconjugate Chemistry , 2017
161.
Passive and active targeting of quantum dots for whole-body fluorescence imaging of breast cancer xenografts
Balalaeva I.V., Zdobnova T.A., Krutova I.V., Brilkina A.A., Lebedenko E.N., Deyev S.M.
Journal of Biophotonics , 2012
162.
Fluorescent immunolabeling of cancer cells by quantum dots and antibody scFv fragment
Zdobnova T.A., Dorofeev S.G., Tananaev P.N., Vasiliev R.B., Balandin T.G., Edelweiss E.F., Stremovskiy O.A., Balalaeva I.V., Turchin I.V., Lebedenko E.N., Zlomanov V.P., Deyev S.M.
Journal of Biomedical Optics , 2009
163.
Recent advances in the development of nanoparticles for multimodality imaging and therapy of cancer
Liu M., Anderson R., Lan X., Conti P.S., Chen K.
Medicinal Research Reviews , 2019
164.
Submicron polymer particles containing fluorescent semiconductor nanocrystals CdSe/ZnS for bioassays
Generalova A.N., Sizova S.V., Zdobnova T.A., Zarifullina M.M., Artemyev M.V., Baranov A.V., Oleinikov V.A., Zubov V.P., Deyev S.M.
Nanomedicine , 2011
165.
Nanoparticles in Targeted Alpha Therapy
Majkowska-Pilip A., Gawęda W., Żelechowska-Matysiak K., Wawrowicz K., Bilewicz A.
Nanomaterials , 2020
166.
Siafaka P.I., Okur N.Ü., Karantas I.D., Okur M.E., Gündoğdu E.A.
Asian Journal of Pharmaceutical Sciences , 2021
167.
Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled α-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles
Zhang X., Chen F., Turker M.Z., Ma K., Zanzonico P., Gallazzi F., Shah M.A., Prater A.R., Wiesner U., Bradbury M.S., McDevitt M.R., Quinn T.P.
Biomaterials , 2020
168.
Engineering Mesoporous Silica Nanoparticles for Targeted Alpha Therapy against Breast Cancer
Pallares R.M., Agbo P., Liu X., An D.D., Gauny S.S., Zeltmann S.E., Minor A.M., Abergel R.J.
ACS applied materials & interfaces , 2020
169.
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
Gawęda W., Pruszyński M., Cędrowska E., Rodak M., Majkowska-Pilip A., Gaweł D., Bruchertseifer F., Morgenstern A., Bilewicz A.
Nanomaterials , 2020
171.
Dual Regioselective Targeting the Same Receptor in Nanoparticle-Mediated Combination Immuno/Chemotherapy for Enhanced Image-Guided Cancer Treatment
Shipunova V.O., Komedchikova E.N., Kotelnikova P.A., Zelepukin I.V., Schulga A.A., Proshkina G.M., Shramova E.I., Kutscher H.L., Telegin G.B., Kabashin A.V., Prasad P.N., Deyev S.M.
ACS Nano , 2020
172.
173.
174.
Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment
175.
Co‐Delivery of 131 I and Prima‐1 by Self‐Assembled CD44‐Targeted Nanoparticles for Anaplastic Thyroid Carcinoma Theranostics
Huang S., Zhang L., Xu M., Li C., Fu H., Huang J., Jin X., Liang S., Wang H.
Advanced healthcare materials , 2020
176.
Radioactive ( 90 Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer
Guryev E.L., Volodina N.O., Shilyagina N.Y., Gudkov S.V., Balalaeva I.V., Volovetskiy A.B., Lyubeshkin A.V., Sen’ A.V., Ermilov S.A., Vodeneev V.A., Petrov R.V., Zvyagin A.V., Alferov Z.I., Deyev S.M.
Proceedings of the National Academy of Sciences of the United States of America , 2018
177.
Stealth Coating of Nanoparticles in Drug-Delivery Systems
Fam S.Y., Chee C.F., Yong C.Y., Ho K.L., Mariatulqabtiah A.R., Tan W.S.
Nanomaterials , 2020
178.
Suppressing Nanoparticle-Mononuclear Phagocyte System Interactions of Two-Dimensional Gold Nanorings for Improved Tumor Accumulation and Photothermal Ablation of Tumors
Liu Y., Wang Z., Liu Y., Zhu G., Jacobson O., Fu X., Bai R., Lin X., Lu N., Yang X., Fan W., Song J., Wang Z., Yu G., Zhang F., et. al.
ACS Nano , 2017
179.
Enhancement of the blood-circulation time and performance of nanomedicines via the forced clearance of erythrocytes
Nikitin M.P., Zelepukin I.V., Shipunova V.O., Sokolov I.L., Deyev S.M., Nikitin P.I.
Nature Biomedical Engineering , 2020
180.
Fast processes of nanoparticle blood clearance: Comprehensive study.
Zelepukin I.V., Yaremenko A.V., Yuryev M.V., Mirkasymov A.B., Sokolov I.L., Deyev S.M., Nikitin P.I., Nikitin M.P.
Journal of Controlled Release , 2020
181.
In vivo blockade of mononuclear phagocyte system with solid nanoparticles: Efficiency and affecting factors.
Mirkasymov A.B., Zelepukin I.V., Nikitin P.I., Nikitin M.P., Deyev S.M.
Journal of Controlled Release , 2021
182.
Long-Term Fate of Magnetic Particles in Mice: A Comprehensive Study.
Zelepukin I.V., Yaremenko A.V., Ivanov I.N., Yuryev M.V., Cherkasov V.R., Deyev S.M., Nikitin P.I., Nikitin M.P.
ACS Nano , 2021
183.
Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs
Beyer I., Cao H., Persson J., Song H., Richter M., Feng Q., Yumul R., van Rensburg R., Li Z., Berenson R., Carter D., Roffler S., Drescher C., Lieber A.
Clinical Cancer Research , 2012
184.
Overcoming physical barriers in cancer therapy
Beyer I., van Rensburg R., Lieber A.
Tissue Barriers , 2013
185.
Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer Therapy
Pitner R., Kim J., Davis-Bergthold J., Turner C., Vassal-Stermann E., Wang H., Adams J., Carter L., Ahlgren J.A., Fender P., Lieber A., Carter D., Gray S.A.
Scientific Reports , 2019
186.
Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology
Shilova O., Shramova E., Proshkina G., Deyev S.
International Journal of Molecular Sciences , 2021
187.
Disassembling a cancer puzzle: Cell junctions and plasma membrane as targets for anticancer therapy
Shilova O.N., Shilov E.S., Lieber A., Deyev S.M.
Journal of Controlled Release , 2018
188.
Junction opener protein increases nanoparticle accumulation in solid tumors
Wang C.E., Yumul R.C., Lin J., Cheng Y., Lieber A., Pun S.H.
Journal of Controlled Release , 2018
189.
Proton re-irradiation of unresectable recurrent head and neck cancers
Gordon K., Gulidov I., Semenov A., Golovanova O., Koryakin S., Makeenkova T., Ivanov S., Kaprin A.
Reports of Practical Oncology and Radiotherapy , 2021
191.
Delivery systems exploiting natural cell transport processes of macromolecules for intracellular targeting of Auger electron emitters
Rosenkranz A.A., Slastnikova T.A., Georgiev G.P., Zalutsky M.R., Sobolev A.S.
Nuclear Medicine and Biology , 2020